查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
癌症生物標記市場 - 全球產業分析，規模，佔有率，成長，趨勢，預測(2022年～2031年)
市場調查報告書
商品編碼
1149261

癌症生物標記市場 - 全球產業分析，規模，佔有率，成長，趨勢，預測(2022年～2031年)

Cancer Biomarkers Market (Type: Protein, Genetics, and Others; and Type of Cancer: Lung, Breast, Leukemia, Melanoma, Colorectal, Prostate, Ovarian, Liver, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031
出版日期: | 出版商: Transparency Market Research | 英文 225 Pages | 商品交期: 2-10個工作天內

價格

本報告提供全球癌症生物標記市場相關調查，提供市場概要，以及2022年～2031年的預測，各類型，各癌症類型，各分析技術，各用途，各地區的趨勢，及加入此市場的主要企業簡介等資訊。

目錄

第1章 序文

第2章 前提與調查手法

第3章 摘要整理:全球癌症生物標記市場

第4章 市場概要

  • 簡介
  • 概要
  • 市場動態
  • 全球癌症生物標記市場分析與預測，2017年～2031年

第5章 主要洞察

第6章 全球癌症生物標記市場分析與預測，各類型

  • 簡介和定義
  • 主要調查結果/開發
  • 各類型的市場價值預測，2017年～2031年
  • 各類型的市場魅力

第7章 全球癌症生物標記市場分析與預測，各癌症類型

  • 簡介和定義
  • 主要調查結果/開發
  • 各癌症類型的市場價值預測，2017年～2031年
  • 各癌症類型的市場魅力

第8章 世界癌症生物標記市場分析與預測，各分析技術

  • 簡介和定義
  • 主要調查結果/開發
  • 各分析技術的市場價值預測，2017年～2031年
  • 各分析技術的市場魅力

第9章 全球癌症生物標記市場分析與預測，各用途

  • 簡介和定義
  • 主要調查結果/開發
  • 各用途的市場價值預測，2017年～2031年
  • 各用途的市場魅力

第10章 全球癌症生物標記市場分析與預測，各地區

  • 主要調查結果
  • 各地區的市場價值預測
    • 北美
    • 歐洲
    • 亞太地區
    • 南美
    • 中東·非洲
  • 各國各地區的市場魅力

第11章 北美的癌症生物標記市場分析與預測

第12章 歐洲的癌症生物標記市場分析與預測

第13章 亞太地區的癌症生物標記市場分析與預測

第14章 南美的癌症生物標記市場分析與預測

第15章 中東·非洲的癌症生物標記市場分析與預測

第16章 競爭情形

  • 市場參與企業-競爭矩陣(層和不同企業規模)
  • 各企業的市場佔有率/排行榜分析(2021年)
  • 企業簡介
    • F. Hoffmann-LA Roche Ltd.
    • Thermo Fisher Scientific, Inc.
    • Abbott Laboratories
    • Bristol-Myers Squibb Company
    • PerkinElmer, Inc.
    • Qiagen NV
    • Siemens AG
    • Exact Sciences Corporation
    • Novartis AG
    • Bio-Rad Laboratories
    • Illumina
    • Agilent Technologies Inc.
    • Hologic, Inc.
    • bioMerieux SA
Product Code: TMRGL479

The report provides revenue of the global cancer biomarkers market for the period 2017-2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global cancer biomarkers market from 2022 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the cancer biomarkers market.

The report delves into the competitive landscape of the global cancer biomarkers market. Key players operating in the global cancer biomarkers market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global cancer biomarkers market profiled in this report.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Cancer Biomarkers Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Segment Definition
    • 4.1.2. Industry Evolution / Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Cancer Biomarkers Market Analysis and Forecasts, 2017 - 2031
    • 4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

  • 5.1. Technological Advancements
  • 5.2. Key Industry Events (Mergers, Acquisitions, Partnerships, etc.)
  • 5.3. Regulatory Scenario by Region/Globally
  • 5.4. COVID-19 Pandemic Impact on Industry (Value Chain and Short / Mid / Long Term Impact)

6. Global Cancer Biomarkers Market Analysis and Forecasts, By Type

  • 6.1. Introduction & Definition
  • 6.2. Key Findings / Developments
  • 6.3. Market Value Forecast By Type, 2017 - 2031
    • 6.3.1. Protein
    • 6.3.2. Genetic
    • 6.3.3. Others
  • 6.4. Market Attractiveness By Type

7. Global Cancer Biomarkers Market Analysis and Forecasts, By Type of Cancer

  • 7.1. Introduction & Definition
  • 7.2. Key Findings / Developments
  • 7.3. Market Value Forecast By Type of Cancer, 2017 - 2031
    • 7.3.1. Lung
    • 7.3.2. Breast
    • 7.3.3. Leukemia
    • 7.3.4. Melanoma
    • 7.3.5. Colorectal
    • 7.3.6. Prostate
    • 7.3.7. Ovarian
    • 7.3.8. Liver
    • 7.3.9. Others
  • 7.4. Market Attractiveness By Type of Cancer

8. Global Cancer Biomarkers Market Analysis and Forecasts, By Profiling Technology

  • 8.1. Introduction & Definition
  • 8.2. Key Findings / Developments
  • 8.3. Market Value Forecast By Profiling Technology, 2017 - 2031
    • 8.3.1. Omics
    • 8.3.2. Imaging
    • 8.3.3. Immunoassay
    • 8.3.4. Bioinformatics
    • 8.3.5. Others
  • 8.4. Market Attractiveness By Profiling Technology

9. Global Cancer Biomarkers Market Analysis and Forecasts, By Application

  • 9.1. Introduction & Definition
  • 9.2. Key Findings / Developments
  • 9.3. Market Value Forecast By Application, 2017 - 2031
    • 9.3.1. Diagnostics
    • 9.3.2. R&D
    • 9.3.3. Prognostics
    • 9.3.4. Others
  • 9.4. Market Attractiveness By Application

10. Global Cancer Biomarkers Market Analysis and Forecasts, By Region

  • 10.1. Key Findings
  • 10.2. Market Value Forecast By Region
    • 10.2.1. North America
    • 10.2.2. Europe
    • 10.2.3. Asia Pacific
    • 10.2.4. Latin America
    • 10.2.5. Middle East & Africa
  • 10.3. Market Attractiveness By Country/Region

11. North America Cancer Biomarkers Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast By Type, 2017 - 2031
    • 11.2.1. Protein
    • 11.2.2. Genetic
    • 11.2.3. Others
  • 11.3. Market Value Forecast By Type of Cancer, 2017 - 2031
    • 11.3.1. Lung
    • 11.3.2. Breast
    • 11.3.3. Leukemia
    • 11.3.4. Melanoma
    • 11.3.5. Colorectal
    • 11.3.6. Prostate
    • 11.3.7. Ovarian
    • 11.3.8. Liver
    • 11.3.9. Others
  • 11.4. Market Value Forecast By Profiling Technology, 2017 - 2031
    • 11.4.1. Omics
    • 11.4.2. Imaging
    • 11.4.3. Immunoassay
    • 11.4.4. Bioinformatics
    • 11.4.5. Others
  • 11.5. Market Value Forecast By Application, 2017 - 2031
    • 11.5.1. Diagnostics
    • 11.5.2. R&D
    • 11.5.3. Prognostics
    • 11.5.4. Others
  • 11.6. Market Value Forecast By Country, 2017 - 2031
    • 11.6.1. U.S.
    • 11.6.2. Canada
  • 11.7. Market Attractiveness Analysis
    • 11.7.1. By Type
    • 11.7.2. By Type of Cancer
    • 11.7.3. By Profiling Technology
    • 11.7.4. By Application
    • 11.7.5. By Country

12. Europe Cancer Biomarkers Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast By Type, 2017 - 2031
    • 12.2.1. Protein
    • 12.2.2. Genetic
    • 12.2.3. Others
  • 12.3. Market Value Forecast By Type of Cancer, 2017 - 2031
    • 12.3.1. Lung
    • 12.3.2. Breast
    • 12.3.3. Leukemia
    • 12.3.4. Melanoma
    • 12.3.5. Colorectal
    • 12.3.6. Prostate
    • 12.3.7. Ovarian
    • 12.3.8. Liver
    • 12.3.9. Others
  • 12.4. Market Value Forecast By Profiling Technology, 2017 - 2031
    • 12.4.1. Omics
    • 12.4.2. Imaging
    • 12.4.3. Immunoassay
    • 12.4.4. Bioinformatics
    • 12.4.5. Others
  • 12.5. Market Value Forecast By Application, 2017 - 2031
    • 12.5.1. Diagnostics
    • 12.5.2. R&D
    • 12.5.3. Prognostics
    • 12.5.4. Others
  • 12.6. Market Value Forecast By Country/Sub-region, 2017 - 2031
    • 12.6.1. Germany
    • 12.6.2. U.K.
    • 12.6.3. France
    • 12.6.4. Spain
    • 12.6.5. Italy
    • 12.6.6. Rest of Europe
  • 12.7. Market Attractiveness Analysis
    • 12.7.1. By Type
    • 12.7.2. By Type of Cancer
    • 12.7.3. By Profiling Technology
    • 12.7.4. By Application
    • 12.7.5. By Country/Sub-region

13. Asia Pacific Cancer Biomarkers Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast By Type, 2017 - 2031
    • 13.2.1. Protein
    • 13.2.2. Genetic
    • 13.2.3. Others
  • 13.3. Market Value Forecast By Type of Cancer, 2017 - 2031
    • 13.3.1. Lung
    • 13.3.2. Breast
    • 13.3.3. Leukemia
    • 13.3.4. Melanoma
    • 13.3.5. Colorectal
    • 13.3.6. Prostate
    • 13.3.7. Ovarian
    • 13.3.8. Liver
    • 13.3.9. Others
  • 13.4. Market Value Forecast By Profiling Technology, 2017 - 2031
    • 13.4.1. Omics
    • 13.4.2. Imaging
    • 13.4.3. Immunoassay
    • 13.4.4. Bioinformatics
    • 13.4.5. Others
  • 13.5. Market Value Forecast By Application, 2017 - 2031
    • 13.5.1. Diagnostics
    • 13.5.2. R&D
    • 13.5.3. Prognostics
    • 13.5.4. Others
  • 13.6. Market Value Forecast By Country/Sub-region, 2017 - 2031
    • 13.6.1. China
    • 13.6.2. Japan
    • 13.6.3. India
    • 13.6.4. Australia & New Zealand
    • 13.6.5. Rest of Asia Pacific
  • 13.7. Market Attractiveness Analysis
    • 13.7.1. By Type
    • 13.7.2. By Type of Cancer
    • 13.7.3. By Profiling Technology
    • 13.7.4. By Application
    • 13.7.5. By Country/Sub-region

14. Latin America Cancer Biomarkers Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast By Type, 2017 - 2031
    • 14.2.1. Protein
    • 14.2.2. Genetic
    • 14.2.3. Others
  • 14.3. Market Value Forecast By Type of Cancer, 2017 - 2031
    • 14.3.1. Lung
    • 14.3.2. Breast
    • 14.3.3. Leukemia
    • 14.3.4. Melanoma
    • 14.3.5. Colorectal
    • 14.3.6. Prostate
    • 14.3.7. Ovarian
    • 14.3.8. Liver
    • 14.3.9. Others
  • 14.4. Market Value Forecast By Profiling Technology, 2017 - 2031
    • 14.4.1. Omics
    • 14.4.2. Imaging
    • 14.4.3. Immunoassay
    • 14.4.4. Bioinformatics
    • 14.4.5. Others
  • 14.5. Market Value Forecast By Application, 2017 - 2031
    • 14.5.1. Diagnostics
    • 14.5.2. R&D
    • 14.5.3. Prognostics
    • 14.5.4. Others
  • 14.6. Market Value Forecast By Country/Sub-region, 2017 - 2031
    • 14.6.1. Brazil
    • 14.6.2. Mexico
    • 14.6.3. Rest of Latin America
  • 14.7. Market Attractiveness Analysis
    • 14.7.1. By Type
    • 14.7.2. By Type of Cancer
    • 14.7.3. By Profiling Technology
    • 14.7.4. By Application
    • 14.7.5. By Country/Sub-region

15. Middle East & Africa Cancer Biomarkers Market Analysis and Forecast

  • 15.1. Introduction
    • 15.1.1. Key Findings
  • 15.2. Market Value Forecast By Type, 2017 - 2031
    • 15.2.1. Protein
    • 15.2.2. Genetic
    • 15.2.3. Others
  • 15.3. Market Value Forecast By Type of Cancer, 2017 - 2031
    • 15.3.1. Lung
    • 15.3.2. Breast
    • 15.3.3. Leukemia
    • 15.3.4. Melanoma
    • 15.3.5. Colorectal
    • 15.3.6. Prostate
    • 15.3.7. Ovarian
    • 15.3.8. Liver
    • 15.3.9. Others
  • 15.4. Market Value Forecast By Profiling Technology, 2017 - 2031
    • 15.4.1. Omics
    • 15.4.2. Imaging
    • 15.4.3. Immunoassay
    • 15.4.4. Bioinformatics
    • 15.4.5. Others
  • 15.5. Market Value Forecast By Application, 2017 - 2031
    • 15.5.1. Diagnostics
    • 15.5.2. R&D
    • 15.5.3. Prognostics
    • 15.5.4. Others
  • 15.6. Market Value Forecast By Country/Sub-region, 2017 - 2031
    • 15.6.1. GCC Countries
    • 15.6.2. South Africa
    • 15.6.3. Rest of Middle East & Africa
  • 15.7. Market Attractiveness Analysis
    • 15.7.1. By Type
    • 15.7.2. By Type of Cancer
    • 15.7.3. By Profiling Technology
    • 15.7.4. By Application
    • 15.7.5. By Country/Sub-region

16. Competition Landscape

  • 16.1. Market Player - Competition Matrix (By Tier and Size of companies)
  • 16.2. Market Share/Ranking Analysis By Company (2021)
  • 16.3. Company Profiles
    • 16.3.1. F. Hoffmann-LA Roche Ltd.
      • 16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.1.2. Product Portfolio
      • 16.3.1.3. SWOT Analysis
      • 16.3.1.4. Strategic Overview
    • 16.3.2. Thermo Fisher Scientific, Inc.
      • 16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.2.2. Product Portfolio
      • 16.3.2.3. SWOT Analysis
      • 16.3.2.4. Strategic Overview
    • 16.3.3. Abbott Laboratories
      • 16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.3.2. Product Portfolio
      • 16.3.3.3. SWOT Analysis
      • 16.3.3.4. Strategic Overview
    • 16.3.4. Bristol-Myers Squibb Company
      • 16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.4.2. Product Portfolio
      • 16.3.4.3. SWOT Analysis
      • 16.3.4.4. Strategic Overview
    • 16.3.5. PerkinElmer, Inc.
      • 16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.5.2. Product Portfolio
      • 16.3.5.3. SWOT Analysis
      • 16.3.5.4. Strategic Overview
    • 16.3.6. Qiagen N.V.
      • 16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.6.2. Product Portfolio
      • 16.3.6.3. SWOT Analysis
      • 16.3.6.4. Strategic Overview
    • 16.3.7. Siemens AG
      • 16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.7.2. Product Portfolio
      • 16.3.7.3. SWOT Analysis
      • 16.3.7.4. Strategic Overview
    • 16.3.8. Exact Sciences Corporation
      • 16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.8.2. Product Portfolio
      • 16.3.8.3. SWOT Analysis
      • 16.3.8.4. Strategic Overview
    • 16.3.9. Novartis AG
      • 16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.9.2. Product Portfolio
      • 16.3.9.3. SWOT Analysis
      • 16.3.9.4. Strategic Overview
    • 16.3.10. Bio-Rad Laboratories
      • 16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.10.2. Product Portfolio
      • 16.3.10.3. SWOT Analysis
      • 16.3.10.4. Strategic Overview
    • 16.3.11. Illumina
      • 16.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.11.2. Product Portfolio
      • 16.3.11.3. SWOT Analysis
      • 16.3.11.4. Strategic Overview
    • 16.3.12. Agilent Technologies Inc.
      • 16.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.12.2. Product Portfolio
      • 16.3.12.3. SWOT Analysis
      • 16.3.12.4. Strategic Overview
    • 16.3.13. Hologic, Inc.
      • 16.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.13.2. Product Portfolio
      • 16.3.13.3. SWOT Analysis
      • 16.3.13.4. Strategic Overview
    • 16.3.14. bioMerieux SA
      • 16.3.14.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.14.2. Product Portfolio
      • 16.3.14.3. SWOT Analysis
      • 16.3.14.4. Strategic Overview

List of Tables

  • Table 01: Global Cancer Biomarkers Market Value (US$ Mn) Forecast, by Type, 2017-2031
  • Table 02: Global Cancer Biomarkers Market Value (US$ Mn) Forecast, by Type of Cancer, 2017-2031
  • Table 03: Global Cancer Biomarkers Market Value (US$ Mn) Forecast, by Technology, 2017-2031
  • Table 04: Global Cancer Biomarkers Market Value (US$ Mn) Forecast, by Application, 2017-2031
  • Table 05: Global Cancer Biomarkers Market Value (US$ Mn) Forecast, by Region, 2017-2031
  • Table 06: North America Cancer Biomarkers Market Value (US$ Mn) Forecast, by Country, 2017-2031
  • Table 07: North America Cancer Biomarkers Market Value (US$ Mn) Forecast, by Type, 2017-2031
  • Table 08: North America Cancer Biomarkers Market Value (US$ Mn) Forecast, by Type of Cancer, 2017-2031
  • Table 09: North America Cancer Biomarkers Market Value (US$ Mn) Forecast, by Technology, 2017-2031
  • Table 10: North America Cancer Biomarkers Market Value (US$ Mn) Forecast, by Application, 2017-2031
  • Table 11: Europe Cancer Biomarkers Market Value (US$ Mn) Forecast, by Country/Sub-Region, 2017-2031
  • Table 12: Europe Cancer Biomarkers Market Value (US$ Mn) Forecast, by Type, 2017-2031
  • Table 13: Europe Cancer Biomarkers Market Value (US$ Mn) Forecast, by Type of Cancer, 2017-2031
  • Table 14: Europe Cancer Biomarkers Market Value (US$ Mn) Forecast, by Technology, 2017-2031
  • Table 15: Europe Cancer Biomarkers Market Value (US$ Mn) Forecast, by Application, 2017-2031
  • Table 16: Asia Pacific Cancer Biomarkers Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 17: Asia Pacific Cancer Biomarkers Market Value (US$ Mn) Forecast, by Type, 2017-2031
  • Table 18: Asia Pacific Cancer Biomarkers Market Value (US$ Mn) Forecast, by Type of Cancer, 2017-2031
  • Table 19: Asia Pacific Cancer Biomarkers Market Value (US$ Mn) Forecast, by Technology, 2017-2031
  • Table 20: Asia Pacific Cancer Biomarkers Market Value (US$ Mn) Forecast, by Application, 2017-2031
  • Table 21: Latin America Cancer Biomarkers Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 22: Latin America Cancer Biomarkers Market Value (US$ Mn) Forecast, by Type, 2017-2031
  • Table 23: Latin America Cancer Biomarkers Market Value (US$ Mn) Forecast, by Type of Cancer, 2017-2031
  • Table 24: Latin America Cancer Biomarkers Market Value (US$ Mn) Forecast, by Technology, 2017-2031
  • Table 25: Latin America Cancer Biomarkers Market Value (US$ Mn) Forecast, by Application, 2017-2031
  • Table 26: Middle East & Africa Cancer Biomarkers Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 27: Middle East & Africa Cancer Biomarkers Market Value (US$ Mn) Forecast, by Type, 2017-2031
  • Table 28: Middle East & Africa Cancer Biomarkers Market Value (US$ Mn) Forecast, by Type of Cancer, 2017-2031
  • Table 29: Middle East & Africa Cancer Biomarkers Market Value (US$ Mn) Forecast, by Technology, 2017-2031
  • Table 30: Middle East & Africa Cancer Biomarkers Market Value (US$ Mn) Forecast, by Application, 2017-2031

List of Figures

  • Figure 01: Global Cancer Biomarkers market Value (US$ Mn) Forecast, 2017-2031
  • Figure 02: Global Cancer Biomarkers market Value Share, by Type, 2021
  • Figure 03: Global Cancer Biomarkers market Value Share, by Profiling Technology, 2021
  • Figure 04: Global Cancer Biomarkers market Value Share, by Cancer, 2021
  • Figure 05: Global Cancer Biomarkers market Value Share, by Application, 2021
  • Figure 06: Global Cancer Biomarkers market Value Share, by Region, 2021
  • Figure 07: Global Cancer Biomarkers Market Value Share Analysis, by Type, 2021 and 2031
  • Figure 08: Global Cancer Biomarkers Market Attractiveness Analysis, by Type, 2022-2031
  • Figure 09: Global Cancer Biomarkers Market Value (US$ Mn), by Protein, 2017-2031
  • Figure 10: Global Cancer Biomarkers Market Value (US$ Mn), by Genetic, 2017-2031
  • Figure 11: Global Cancer Biomarkers Market Value (US$ Mn), by Others, 2017-2031
  • Figure 12: Global Cancer Biomarkers Market Value Share Analysis, by Type of Cancer, 2021 and 2031
  • Figure 13: Global Cancer Biomarkers Market Attractiveness Analysis, by Type of Cancer, 2022-2031
  • Figure 14: Global Cancer Biomarkers Market Revenue (US$ Mn), by Lung, 2017-2031
  • Figure 15: Global Cancer Biomarkers Market Revenue (US$ Mn), by Breast, 2017-2031
  • Figure 16: Global Cancer Biomarkers Market Revenue (US$ Mn), by Leukemia, 2017-2031
  • Figure 17: Global Cancer Biomarkers Market Revenue (US$ Mn), by Melonoma, 2017-2031
  • Figure 18: Global Cancer Biomarkers Market Revenue (US$ Mn), by Colorectal, 2017-2031
  • Figure 19: Global Cancer Biomarkers Market Revenue (US$ Mn), by Prostate, 2017-2031
  • Figure 20: Global Cancer Biomarkers Market Revenue (US$ Mn), by Ovarian, 2017-2031
  • Figure 21: Global Cancer Biomarkers Market Revenue (US$ Mn), by Liver, 2017-2031
  • Figure 22: Global Cancer Biomarkers Market Revenue (US$ Mn), by Others, 2017-2031
  • Figure 23: Global Cancer Biomarkers Market Value Share Analysis, by Technology, 2021 and 2031
  • Figure 24: Global Cancer Biomarkers Market Attractiveness Analysis, by Technology, 2022-2031
  • Figure 25: Global Cancer Biomarkers Market Revenue (US$ Mn), by Omics, 2017-2031
  • Figure 26: Global Cancer Biomarkers Market Revenue (US$ Mn), by Imaging, 2017-2031
  • Figure 27: Global Cancer Biomarkers Market Revenue (US$ Mn), by Immunoassay, 2017-2031
  • Figure 28: Global Cancer Biomarkers Market Revenue (US$ Mn), by Bioinformatics, 2017-2031
  • Figure 29: Global Cancer Biomarkers Market Revenue (US$ Mn), by Others, 2017-2031
  • Figure 30: Global Cancer Biomarkers Market Value Share Analysis, by Application, 2021 and 2031
  • Figure 31: Global Cancer Biomarkers Market Attractiveness Analysis, by Application, 2022-2031
  • Figure 32: Global Cancer Biomarkers Market Revenue (US$ Mn), by Diagnostics, 2017-2031
  • Figure 33: Global Cancer Biomarkers Market Revenue (US$ Mn), by R&D, 2017-2031
  • Figure 34: Global Cancer Biomarkers Market Revenue (US$ Mn), by Prognostics, 2017-2031
  • Figure 35: Global Cancer Biomarkers Market Revenue (US$ Mn), by Others, 2017-2031
  • Figure 36: Global Cancer Biomarkers Market Value Share Analysis, by Region, 2021 and 2031
  • Figure 37: Global Cancer Biomarkers Market Attractiveness Analysis, by Region, 2022-2031
  • Figure 38: North America Cancer Biomarkers Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 39: North America Cancer Biomarkers Market Value Share Analysis, by Country, 2021 and 2031
  • Figure 40: North America Cancer Biomarkers Market Attractiveness Analysis, by Country, 2022-2031
  • Figure 41: North America Cancer Biomarkers Market Value Share Analysis, by Type, 2021 and 2031
  • Figure 42: North America Cancer Biomarkers Market Attractiveness Analysis, by Type, 2022-2031
  • Figure 43: North America Cancer Biomarkers Market Value Share Analysis, by Type of Cancer, 2021 and 2031
  • Figure 44: North America Cancer Biomarkers Market Attractiveness Analysis, by Type of Cancer, 2022-2031
  • Figure 45: North America Cancer Biomarkers Market Value Share Analysis, by Technology, 2021 and 2031
  • Figure 46: North America Cancer Biomarkers Market Attractiveness Analysis, by Technology, 2022-2031
  • Figure 47: North America Cancer Biomarkers Market Value Share Analysis, by Application, 2021 and 2031
  • Figure 48: North America Cancer Biomarkers Market Attractiveness Analysis, by Application, 2022-2031
  • Figure 49: Europe Cancer Biomarkers Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 50: Europe Cancer Biomarkers Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
  • Figure 51: Europe Cancer Biomarkers Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
  • Figure 52: Europe Cancer Biomarkers Market Value Share Analysis, by Type, 2021 and 2031

Figure53 11: Europe Cancer Biomarkers Market Attractiveness Analysis, by Type, 2022-2031

  • Figure 54: Europe Cancer Biomarkers Market Value Share Analysis, by Type of Cancer, 2021 and 2031
  • Figure 55: Europe Cancer Biomarkers Market Attractiveness Analysis, by Type of Cancer, 2022-2031
  • Figure 56: Europe Cancer Biomarkers Market Value Share Analysis, by Technology, 2021 and 2031
  • Figure 57: Europe Cancer Biomarkers Market Attractiveness Analysis, by Technology, 2022-2031
  • Figure 58: Europe Cancer Biomarkers Market Value Share Analysis, by Application, 2021 and 2031
  • Figure 59: Europe Cancer Biomarkers Market Attractiveness Analysis, by Application, 2022-2031
  • Figure 60: Asia Pacific Cancer Biomarkers Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 61: Asia Pacific Cancer Biomarkers Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
  • Figure 62: Asia Pacific Cancer Biomarkers Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
  • Figure 63: Asia Pacific Cancer Biomarkers Market Value Share Analysis, by Type, 2021 and 2031
  • Figure 64: Asia Pacific Cancer Biomarkers Market Attractiveness Analysis, by Type, 2022-2031
  • Figure 65: Asia Pacific Cancer Biomarkers Market Value Share Analysis, by Type of Cancer, 2021 and 2031
  • Figure 66: Asia Pacific Cancer Biomarkers Market Attractiveness Analysis, by Type of Cancer, 2022-2031
  • Figure 67: Asia Pacific Cancer Biomarkers Market Value Share Analysis, by Technology, 2021 and 2031
  • Figure 68: Asia Pacific Cancer Biomarkers Market Attractiveness Analysis, by Technology, 2022-2031
  • Figure 69: Asia Pacific Cancer Biomarkers Market Value Share Analysis, by Application, 2021 and 2031
  • Figure 70: Asia Pacific Cancer Biomarkers Market Attractiveness Analysis, by Application, 2022-2031
  • Figure 71: Latin America Cancer Biomarkers Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 72: Latin America Cancer Biomarkers Market Value Share Analysis, by Country/Sub-Region, 2021 and 2031
  • Figure 73: Latin America Cancer Biomarkers Market Attractiveness Analysis, by Country/Sub-Region, 2021-2031
  • Figure 74: Latin America Cancer Biomarkers Market Value Share Analysis, by Type, 2021 and 2031
  • Figure 75: Latin America Cancer Biomarkers Market Attractiveness Analysis, by Type, 2022-2031
  • Figure 76: Latin America Cancer Biomarkers Market Value Share Analysis, by Type of Cancer, 2021 and 2031
  • Figure 77: Latin America Cancer Biomarkers Market Attractiveness Analysis, by Type of Cancer, 2022-2031
  • Figure 78: Latin America Cancer Biomarkers Market Value Share Analysis, by Technology, 2021 and 2031
  • Figure 79: Latin America Cancer Biomarkers Market Attractiveness Analysis, by Technology, 2022-2031
  • Figure 80: Latin America Cancer Biomarkers Market Value Share Analysis, by Application, 2021 and 2031
  • Figure 81: Latin America Cancer Biomarkers Market Attractiveness Analysis, by Application, 2022-2031
  • Figure 82: Middle East & Africa Cancer Biomarkers Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 83: Middle East & Africa Cancer Biomarkers Market Value Share Analysis, by Country/Sub-Region, 2021 and 2031
  • Figure 84: Middle East & Africa Cancer Biomarkers Market Attractiveness Analysis, by Country/Sub-Region, 2021-2031
  • Figure 85: Middle East & Africa Cancer Biomarkers Market Value Share Analysis, by Type, 2021 and 2031
  • Figure 86: Middle East & Africa Cancer Biomarkers Market Attractiveness Analysis, by Type, 2022-2031
  • Figure 87: Middle East & Africa Cancer Biomarkers Market Value Share Analysis, by Type of Cancer, 2021 and 2031
  • Figure 88: Middle East & Africa Cancer Biomarkers Market Attractiveness Analysis, by Type of Cancer, 2022-2031
  • Figure 89: Middle East & Africa Cancer Biomarkers Market Value Share Analysis, by Technology, 2021 and 2031
  • Figure 90: Middle East & Africa Cancer Biomarkers Market Attractiveness Analysis, by Technology, 2022-2031
  • Figure 91: Middle East & Africa Cancer Biomarkers Market Value Share Analysis, by Application, 2021 and 2031
  • Figure 92: Middle East & Africa Cancer Biomarkers Market Attractiveness Analysis, by Application, 2022-2031